Key findings and emerging evidence in MAFLD, focusing on its connection to diabetes and metabolic health. Research supports a deeper understanding of disease progression and informs evolving care approaches.
| Title | Link |
| Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary | Click here |
| Detecting at-risk steatotic liver disease and liver fibrosis in the community (Hepatology 2025) | Click here |
| Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association | Click here |
| An Australian Community-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Care Pathway for People with Type 2 Diabetes: Barriers and Considerations | Click here |
| EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) | Click here |
| Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD) | Click here |
| Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics | Click here |
| Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis in Diabetology | Click here |
| Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease | Click here |
The National Association of Diabetes Centres (NADC) is a national collective of organisations that are involved either directly or indirectly in diabetes services and care.
